Showing results (1-10 of 286) with videos related to
Sort By:
Pageof 29
Patient Preference and Adherence|September 9, 2015
Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDSRoberta Prinapori, Antonio Di BiagioVirology Journal|November 24, 2018
Treatment of hepatitis C virus genotype 4 in the DAA eraAntonio Di Biagio, Lucia Taramasso, Giovanni CenderelloCurrent Infectious Disease Reports|May 9, 2008
Infectious complications of cancer chemotherapy in HIV patientsRaffaella Rosso, Antonio Di Biagio, Claudio ViscoliCurrent Opinion in Infectious Diseases|December 15, 2025
Cutaneous manifestations associated with HIV preexposure prophylaxis: what to expect and when to worryLorenzo Costacurta, Antonio Di Biagio, Lucia TaramassoVirulence|March 8, 2016
Bloodstream infections in HIV-infected patientsLucia Taramasso, Paola Tatarelli, Antonio Di BiagioExpert Opinion on Pharmacotherapy|June 14, 2021
Evaluating fostemsavir as a therapeutic option for patients with HIVMarco Berruti, Rachele Pincino, Lucia Taramasso, et al.Minerva Medica|October 21, 2021
SARS-CoV-2, alcohol consumption and liver injuryGianni Testino, Antonio DI Biagio, Sharmila Fagoonee, et al.AIDS (London, England)|April 10, 2020
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimenLucia Taramasso, Marco Berruti, Federica Briano, et al.Journal of the International Association of Providers of AIDS Care|February 26, 2019
Maintenance of Viral Suppression after Optimization Therapy from Etravirine Plus Raltegravir to Rilpivirine Plus Dolutegravir in HIV-1-Infected PatientsNiccolò Riccardi, Filippo Del Puente, Lucia Taramasso, et al.Current Pharmaceutical Biotechnology|April 8, 2011
HIV and accelerated atheroprogression: role of antiretroviral therapyAntonio Di Biagio, Valerio Del Bono, Raffaella Rosso, et al.Pageof 29